Haisco and AirNexis Forge Major Licensing Deal for Groundbreaking Drug HSK39004
In a landmark agreement solidifying China's position in the global pharmaceutical landscape, Haisco Pharmaceutical Group Co., Ltd. has unveiled an exclusive licensing deal that grants AirNexis the rights to its innovative medication HSK39004. This drug, known for its dual-target mechanism, specifically addresses chronic obstructive pulmonary disease (COPD), potentially altering the treatment landscape for millions of patients worldwide.
This partnership not only emphasizes Haisco's commitment to international growth and innovative drug development but also marks an extraordinary investment in the biopharmaceutical sphere, with the total transaction value exceeding USD 1 billion. The deal, announced on January 9, 2026, includes an upfront payment of USD 108 million, composed of USD 40 million in cash and USD 68 million in equity from AirNexis. Additionally, Haisco stands to gain up to USD 955 million in future development milestones and tiered royalties that could reach the mid-teens percentage on net sales post-launch.
HSK39004 is noteworthy as a proprietary PDE3/4 dual inhibitor that combines potent bronchodilatory and anti-inflammatory effects, aiming to provide enhanced maintenance therapy for COPD patients. What sets this drug apart is its rapid delivery system, as it comes in two formulations: an inhalation suspension and a dry powder inhaler (DPI). The DPI formulation allows for a notably quick inhalation process, taking only five seconds, which is poised to significantly improve patient adherence to treatment regimens. Currently, both formulations are undergoing Phase II clinical trials in China, where preliminary studies have already shown promising results in terms of bronchodilation and safety.
Supporting this initiative, AirNexis has garnered the backing of esteemed life sciences investors, including Frazier Life Sciences, OrbiMed, and Goldman Sachs Alternatives, who collectively have pledged USD 200 million to propel this endeavor. Frazier Life Sciences, a key player in the biopharmaceutical investment realm, has reported raising over USD 5.3 billion since 2016, implying a robust backing for the commercialization of innovative drug solutions. This collaboration is further reinforced by the presence of top-tier global life sciences institutions, creating a powerful synergy aimed at transforming COPD treatment on a global scale.
As Haisco looks forward, the company continues to prioritize the development of original drugs to meet the urgent clinical needs present in various therapeutic areas. With over 50 research and development programs underway, including more than ten at pivotal clinical stages, Haisco's commitment to innovation and global market expansion remains steadfast. The collaboration with AirNexis is fundamental to this vision, strategically aligning their efforts to fortify their presence in the international market while ensuring sustainable cash flow and return on investment.
This partnership signals a transformative shift in Haisco's global strategy, moving beyond traditional licensing agreements to a more integrated and collaborative model, thereby enhancing operational alignment with international partners. The significance of such a deal not only heralds the launch of HSK39004 in the global market but also symbolizes Haisco's broader ambitions to establish itself as a leader in the international pharmaceutical arena. The future outlook is promising as Haisco aims to continue its trajectory of innovation, bringing original Chinese-developed medicines to patients around the world, and thereby improving the quality of life for many suffering from chronic respiratory conditions.
This partnership not only emphasizes Haisco's commitment to international growth and innovative drug development but also marks an extraordinary investment in the biopharmaceutical sphere, with the total transaction value exceeding USD 1 billion. The deal, announced on January 9, 2026, includes an upfront payment of USD 108 million, composed of USD 40 million in cash and USD 68 million in equity from AirNexis. Additionally, Haisco stands to gain up to USD 955 million in future development milestones and tiered royalties that could reach the mid-teens percentage on net sales post-launch.
HSK39004 is noteworthy as a proprietary PDE3/4 dual inhibitor that combines potent bronchodilatory and anti-inflammatory effects, aiming to provide enhanced maintenance therapy for COPD patients. What sets this drug apart is its rapid delivery system, as it comes in two formulations: an inhalation suspension and a dry powder inhaler (DPI). The DPI formulation allows for a notably quick inhalation process, taking only five seconds, which is poised to significantly improve patient adherence to treatment regimens. Currently, both formulations are undergoing Phase II clinical trials in China, where preliminary studies have already shown promising results in terms of bronchodilation and safety.
Supporting this initiative, AirNexis has garnered the backing of esteemed life sciences investors, including Frazier Life Sciences, OrbiMed, and Goldman Sachs Alternatives, who collectively have pledged USD 200 million to propel this endeavor. Frazier Life Sciences, a key player in the biopharmaceutical investment realm, has reported raising over USD 5.3 billion since 2016, implying a robust backing for the commercialization of innovative drug solutions. This collaboration is further reinforced by the presence of top-tier global life sciences institutions, creating a powerful synergy aimed at transforming COPD treatment on a global scale.
As Haisco looks forward, the company continues to prioritize the development of original drugs to meet the urgent clinical needs present in various therapeutic areas. With over 50 research and development programs underway, including more than ten at pivotal clinical stages, Haisco's commitment to innovation and global market expansion remains steadfast. The collaboration with AirNexis is fundamental to this vision, strategically aligning their efforts to fortify their presence in the international market while ensuring sustainable cash flow and return on investment.
This partnership signals a transformative shift in Haisco's global strategy, moving beyond traditional licensing agreements to a more integrated and collaborative model, thereby enhancing operational alignment with international partners. The significance of such a deal not only heralds the launch of HSK39004 in the global market but also symbolizes Haisco's broader ambitions to establish itself as a leader in the international pharmaceutical arena. The future outlook is promising as Haisco aims to continue its trajectory of innovation, bringing original Chinese-developed medicines to patients around the world, and thereby improving the quality of life for many suffering from chronic respiratory conditions.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.